Longevity of immunity following COVID-19 vaccination: a comprehensive review of the currently approved vaccines.
Antibody persistence
COVID-19
Cell-mediated immunity
Humoral immunity
Immunogenicity
Long-term immunity
Long-term protection
SARS-CoV-2
Vaccines
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
30 11 2022
30 11 2022
Historique:
pubmed:
14
4
2022
medline:
15
6
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
It is unknown how long the immunity following COVID-19 vaccination lasts. The current systematic review provides a perspective on the persistence of various antibodies for available vaccines.Both the BNT162b2 and the mRNA-1273 induce the production of IgA antibodies, reflecting the possible prevention of the asymptomatic spread. The mRNA-1273 vaccine's antibodies were detectable until 6 months, followed by the AZD1222, 3 months, the Ad26.COV2.S and the BNT162b2 vaccines within 2 months.The BNT162b2 produced anti-spike IgGs 11 days after the first dose and peaked at day 21, whereas the AZD1222 induced a neutralizing effect 22 days after the first dose.These vaccines induce T-cell mediated immune responses too. Each one of the AZD1222, Ad26.COV2.S, mRNA-1273 mediates T-cell response immunity at days 14-22, 15, and 43 after the first dose, respectively. Whereas for the BNT162b1 and BNT162b2 vaccines, T-cell immunity is induced 7 days and 12 weeks after the booster dose, respectively.
Identifiants
pubmed: 35417285
doi: 10.1080/21645515.2022.2037384
pmc: PMC9115789
doi:
Substances chimiques
Ad26COVS1
JT2NS6183B
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
ChAdOx1 nCoV-19
B5S3K2V0G8
2019-nCoV Vaccine mRNA-1273
EPK39PL4R4
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2037384Références
Diagn Microbiol Infect Dis. 2022 Jan;102(1):115565
pubmed: 34731684
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
Nature. 2020 Oct;586(7830):594-599
pubmed: 32998157
Control Clin Trials. 1996 Feb;17(1):1-12
pubmed: 8721797
Vaccine. 2000 Nov 22;19(7-8):877-85
pubmed: 11115711
Lancet Respir Med. 2021 Apr;9(4):e42-e43
pubmed: 33684355
Bull World Health Organ. 2008 Feb;86(2):140-6
pubmed: 18297169
Nature. 2020 Oct;586(7830):589-593
pubmed: 32785213
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Lancet. 2021 Dec 19;396(10267):1979-1993
pubmed: 33220855
Pharmaceuticals (Basel). 2021 Apr 25;14(5):
pubmed: 33923054
Physiol Res. 2020 Jul 16;69(3):379-388
pubmed: 32469225
Rev Med Virol. 2022 Jan;32(1):e2260
pubmed: 34043841
Clin Drug Investig. 2021 Jun;41(6):499-509
pubmed: 33754328
Eur J Clin Microbiol Infect Dis. 2021 Aug;40(8):1713-1719
pubmed: 33738620
Biochem Biophys Res Commun. 2021 Jan 29;538:226-230
pubmed: 33139015
Nat Rev Immunol. 2021 Nov;21(11):687-688
pubmed: 34497383
Nature. 2021 Apr;592(7855):616-622
pubmed: 33567448
N Engl J Med. 2021 Jun 10;384(23):2259-2261
pubmed: 33822494
Nat Rev Drug Discov. 2018 Apr;17(4):261-279
pubmed: 29326426
Vaccines (Basel). 2020 Oct 01;8(4):
pubmed: 33019589
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Mar;23(3):221-228
pubmed: 33691913
Nat Rev Immunol. 2021 Apr;21(4):195-197
pubmed: 33674759
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Lancet. 2021 Mar 6;397(10277):881-891
pubmed: 33617777
Dement Geriatr Cogn Disord. 2001 May-Jun;12(3):232-6
pubmed: 11244218
Otolaryngol Head Neck Surg. 2021 Feb;164(2):305-307
pubmed: 33320052
Vaccines (Basel). 2020 Dec 09;8(4):
pubmed: 33316990
Clin Chem Lab Med. 2021 Apr 12;59(9):1585-1591
pubmed: 33838087
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Phys Ther. 2008 Feb;88(2):156-75
pubmed: 18073267
Lancet Glob Health. 2021 Jun;9(6):e742-e743
pubmed: 33675693
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381